Related Experiment Videos
Possible mitoxantrone-induced amenorrhea
Cancer Treatment Reports
|May 1, 1986
Summary
Mitoxantrone chemotherapy can cause premature menopause in women, leading to amenorrhea (absence of menstruation) and hot flashes. This ovarian toxicity, previously unreported for mitoxantrone, highlights potential long-term health consequences for patients.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Adenoid cystic carcinoma is a rare malignancy.
- Mitoxantrone is an antineoplastic agent used in cancer treatment.
- Chemotherapy can induce ovarian dysfunction.
Observation:
- A patient with adenoid cystic carcinoma received mitoxantrone (12 mg/m2 every 3 weeks).
- After five doses, the patient experienced amenorrhea and vasomotor instability (hot flashes).
- Hormonal assays confirmed a postmenopausal state.
Findings:
- Mitoxantrone treatment resulted in chemotherapy-induced ovarian failure.
- The likely mechanism involves direct toxic effects of mitoxantrone on ovarian tissue.
- This represents a previously unreported adverse effect of mitoxantrone.
Implications:
- Chemotherapy-induced ovarian failure has significant long-term health consequences for women.
- Increased reporting of ovarian dysfunction with mitoxantrone is anticipated as its use becomes more widespread.
- Clinicians should monitor for and counsel patients on potential reproductive toxicity.